Today: 27 April 2026
Meta stock ticks up after-hours as Ray-Ban Display rollout is paused on U.S. demand
6 January 2026
1 min read

Meta stock ticks up after-hours as Ray-Ban Display rollout is paused on U.S. demand

New York, Jan 6, 2026, 16:49 EST — After-hours

Meta Platforms Inc (META.O) shares were up about 0.3% at $660.62 in after-hours trading on Tuesday after the company paused international expansion of its Ray-Ban Display smart glasses. Meta cited limited supply and heavy U.S. demand, and said waitlists now stretch well into 2026, forcing it to reassess launches planned for the UK, France, Italy and Canada. The stock traded between $651.92 and $665.47 in the regular session, and IDC’s Francisco Jeronimo put first-quarter unit sales at about 15,000, or roughly 6% market share in the category.

The move matters because the glasses are a key test of Meta’s bet that consumer devices can deepen engagement and open new growth beyond advertising. Strong demand supports that story, but supply bottlenecks and a delayed overseas rollout can cap near-term sales and keep investors focused on execution.

Tech shares helped lift Wall Street on Tuesday as investors leaned into AI-linked trades heading into fourth-quarter earnings season. Jed Ellerbroek, a portfolio manager at Argent Capital, said he expects “a very strong earnings season for Big Tech,” with capital spending forecasts likely to move higher again. Reuters

At CES in Las Vegas, Meta outlined new software features tied to its Neural Band wrist device. The Verge reported Meta will add a teleprompter mode that pulls notes from a phone, and an EMG-based handwriting option — using muscle signals — to reply to messages in WhatsApp and Messenger, with a phased rollout starting this week. The report said Meta is also expanding its pedestrian navigation beta to Denver, Las Vegas, Portland and Salt Lake City.

Meta also named C.J. Mahoney, a former Microsoft legal executive and onetime deputy U.S. trade representative, as chief legal officer, reporting to Chief Executive Mark Zuckerberg. Mahoney starts Wednesday, replacing Jennifer Newstead, who said she will leave to become general counsel at Apple in March. Zuckerberg said Mahoney brings “world-class legal expertise” as Meta faces lawsuits and criticism over protections for young users.

But demand that outstrips supply can cut both ways for investors: it validates the product, yet pushes revenue out and raises questions about production capacity. Any sign that hardware economics, AI spending or legal and regulatory risks are worsening could weigh on a stock that already trades at a premium to the broader market.

Traders are likely to watch for any revision to Meta’s rollout timetable and fresh signals on production. The next macro test is the U.S. December nonfarm payrolls report due Friday, Jan. 9, while Meta has yet to list an earnings date on its investor events calendar.

Stock Market Today

  • S&P 500 and Nasdaq Set for Intraday Records Amid Sector Strength and Earnings Focus
    April 27, 2026, 5:02 PM EDT. The S&P 500 and Nasdaq Composite are poised for their 12th and eighth intraday record highs of the year, respectively, driven by strong performances in semiconductors, mega-cap tech, and industrial sectors. Fresh highs emerged in multiple exchange-traded funds (ETFs) including small-cap tech, materials, and sectors like technology and semiconductors. Notable stocks hitting highs span various industries: Casey's in consumer staples; Kirby and Cummins in industrials; Nucor and Linde in materials; and big tech names like Alphabet, Nvidia, Intel, and Taiwan Semiconductor. The momentum continues despite recent concerns over the Strait of Hormuz closure and key May earnings reports. Investors remain focused on the resilience of mega-cap tech and cyclicals, underscoring a broad market advance across sectors and styles.

Latest article

Sagimet Stock Surges as $175 Million Raise Sharpens Acne Drug Push

Sagimet Stock Surges as $175 Million Raise Sharpens Acne Drug Push

27 April 2026
Sagimet Biosciences priced 29.17 million shares at $6 each, seeking to raise $175 million to fund a U.S. Phase 3 acne trial for denifanstat. Shares rose 38% to $8.12 on heavy volume Monday. The company will delay further work on its MASH liver-disease program unless it secures non-dilutive funding. Sagimet reported about $104.5 million in cash and equivalents.
Synopsys stock climbs as CES automotive push and chip rally lift SNPS shares
Previous Story

Synopsys stock climbs as CES automotive push and chip rally lift SNPS shares

Western Digital (WDC) stock jumps 17% after Nvidia CES storage talk sparks AI-driven rally
Next Story

Western Digital (WDC) stock jumps 17% after Nvidia CES storage talk sparks AI-driven rally

Go toTop